Fig. 3From: miRNA-106a directly targeting RARB associates with the expression of Na+/I− symporter in thyroid cancer by regulating MAPK signaling pathway a, MTT Cell viability assays: relative cell viability in parental 8505C and transfected sublines [*, P < 0.01, miR106a(−) and U0126 vs. control; #, P < 0.01, miR106a(−) + RARB(−) and miR106a(−) + MAP3K2 vs. miR106a(−)]; b, MTT Cell viability assays: relative cell viability in parental CGTH-W3 and transfected sublines [*, P < 0.01, miR106a(+) and RARB(−) vs. control; #, P < 0.01, miR106a(+) + U0126 vs. miR106a(+)]; c and d, flow cytometry analysis of cell cycle in 8505C and 8505C-miR106a(−)Back to article page